Last Close
Apr 08  •  04:00PM ET
21.51
Dollar change
+1.06
Percentage change
5.18
%
Index
-
P/E
-
EPS (ttm)
-5.27
Insider Own
15.81%
Shs Outstand
47.12M
Perf Week
2.97%
Market Cap
1.20B
Forward P/E
-
EPS next Y
-0.29
Insider Trans
-27.74%
Shs Float
46.86M
Perf Month
-6.07%
Enterprise Value
1.02B
PEG
-
EPS next Q
-0.13
Inst Own
35.32%
Perf Quarter
29.34%
Income
-147.34M
P/S
-
EPS this Y
12.07%
Inst Trans
263.54%
Perf Half Y
61.85%
Sales
0.00M
P/B
6.01
EPS next Y
68.37%
ROA
-98.43%
Perf YTD
12.21%
Book/sh
3.58
P/C
6.17
EPS next 5Y
-
ROE
-150.23%
52W High
26.18 -17.85%
Perf Year
201.05%
Cash/sh
3.49
P/FCF
-
EPS past 3/5Y
5.33% 18.68%
ROIC
-84.59%
52W Low
6.69 221.44%
Perf 3Y
25.06%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
6.00% 6.59%
Perf 5Y
-63.73%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
10.06%
Oper. Margin
-
ATR (14)
1.37
Perf 10Y
-93.84%
Dividend Ex-Date
-
Quick Ratio
3.67
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
54.93
Dividend Gr. 3/5Y
- -
Current Ratio
3.67
EPS Q/Q
-2.69%
SMA20
6.48%
Beta
-1.04
Payout
-
Debt/Eq
0.13
Sales Q/Q
-
SMA50
0.65%
Rel Volume
0.36
Prev Close
20.45
Employees
125
LT Debt/Eq
0.03
SMA200
40.87%
Avg Volume
333.08K
Price
21.51
IPO
Oct 22, 2014
Option/Short
No / Yes
Trades
Volume
118,791
Change
5.18%
Date Action Analyst Rating Change Price Target Change
Dec-15-25Initiated Cantor Fitzgerald Overweight $42
Dec-03-25Initiated Guggenheim Buy $35
May-29-25Resumed Goldman Sell $7.25
Jan-04-23Upgrade Societe Generale Hold → Buy
Dec-16-22Downgrade Goldman Neutral → Sell
May-10-22Downgrade Goldman Buy → Neutral $6 → $1.50
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Apr-02-26 04:30PM
02:20AM
Mar-26-26 05:19PM
05:06PM
Mar-24-26 04:30PM
04:30PM Loading…
Mar-04-26 04:30PM
Mar-03-26 04:30PM
Feb-28-26 02:25PM
Feb-13-26 07:13AM
Feb-10-26 04:30PM
Feb-09-26 04:30PM
Feb-05-26 04:30PM
Jan-16-26 06:11PM
Jan-12-26 04:00PM
Jan-07-26 04:00PM
04:00PM Loading…
Jan-05-26 04:00PM
Dec-21-25 07:31AM
Dec-17-25 04:01PM
08:42AM
07:27AM
Dec-16-25 04:05PM
Dec-15-25 09:16AM
Dec-03-25 09:15AM
Dec-02-25 04:00PM
Nov-11-25 11:50PM
Nov-04-25 04:30PM
Nov-03-25 04:30PM
04:25PM
Oct-31-25 09:40AM
Oct-30-25 04:30PM
03:00AM Loading…
03:00AM
Oct-29-25 06:47PM
Oct-28-25 04:25PM
Oct-17-25 09:16AM
Oct-06-25 05:02PM
Sep-23-25 05:04AM
Sep-18-25 04:30PM
Sep-05-25 04:30PM
Sep-03-25 04:30PM
Aug-01-25 04:05PM
Jul-29-25 04:17PM
04:08PM
Jul-28-25 04:30PM
Jul-24-25 07:40AM
Jul-22-25 04:30PM
Jul-09-25 07:20AM
Jun-25-25 04:15PM
Jun-23-25 09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
Jun-12-25 04:05PM
Jun-11-25 04:30PM
Jun-04-25 04:32PM
Jun-03-25 04:30PM
May-21-25 09:40AM
May-16-25 12:00PM
08:50AM
May-15-25 04:30PM
May-06-25 04:30PM
May-05-25 04:30PM
Apr-30-25 04:00PM
08:50AM
06:25AM
Apr-14-25 08:50AM
Apr-11-25 04:30PM
Apr-10-25 07:00AM
Mar-27-25 10:30PM
Mar-24-25 03:09AM
02:30AM
Feb-25-25 04:01PM
Jan-13-25 04:05PM
Jan-08-25 04:05PM
Dec-12-24 09:59AM
Dec-11-24 04:05PM
Dec-02-24 04:30PM
Nov-11-24 04:30PM
Nov-06-24 04:30PM
Oct-24-24 08:31AM
Oct-22-24 04:45PM
Oct-18-24 04:30PM
Oct-14-24 04:30PM
Sep-23-24 04:30PM
Sep-04-24 04:30PM
Aug-02-24 04:30PM
Jul-30-24 08:55PM
05:30PM
04:30PM
Jul-29-24 01:30AM
Jul-08-24 04:30PM
Jun-05-24 04:30PM
Jun-04-24 04:30PM
May-31-24 09:51AM
May-30-24 04:30PM
May-17-24 04:30PM
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohideen PharisChief Medical OfficerJan 29 '26Sale4.865342,595144,995Feb 02 04:30 PM
EPIC BpifranceMember of 10% owner groupDec 17 '25Sale4.852,076,99010,070,2328,595,472Dec 19 04:04 PM
EPIC BpifranceMember of 10% owner groupDec 18 '25Sale4.191,292,1035,413,9127,303,369Dec 19 04:04 PM
Mohideen PharisChief Medical OfficerNov 20 '25Sale2.886,49618,708103,153Nov 25 04:15 PM
Mohideen PharisChief Medical OfficerNov 21 '25Sale2.771,6244,498101,529Nov 25 04:15 PM
Mohideen PharisChief Medical OfficerJul 29 '25Sale2.224641,030109,649Jul 31 04:15 PM
Mohideen PharisChief Medical OfficerMay 22 '25Sale1.84397730110,113May 27 04:10 PM